REGN Shorts Ease Ahead of Q3 Results

Regeneron Pharmaceuticals enters its October 30 Q3 earnings report with short sellers cutting positions, options traders leaning bullish, and a run of analyst target increases that has pushed the consensus well above current levels.

Short interest has fallen 16% over the past month, dropping to 2.1% of the free float, roughly 2.15 million shares. The week-on-week reading is slightly higher, up about 2%, but the month-long trend is unambiguous: bears have been covering. With borrow availability at the maximum reading the data captures, there is no scarcity of shares to borrow, so the retreat reflects a change in conviction rather than a short squeeze. Cost to borrow has nearly doubled over the past week to 0.35%, but at that level it remains trivially cheap, so the move carries no practical signal for positioning pressure.

Options reinforce the same lean. The put-call ratio fell to 0.80 on October 20, more than two standard deviations below its 20-day mean of 0.83. That is a tight-range stock where such a move stands out: the PCR has barely deviated from 0.83 for weeks, making the sudden drop toward calls the most pronounced shift in recent months. The 52-week PCR range runs from 0.44 to 1.13, so the stock is far from either extreme, but the direction of travel this week is clearly toward call demand rather than hedging.

The Street has been raising targets consistently. TD Cowen lifted its target to $980 from $960 this week, keeping its Buy. UBS upgraded to Buy on October 15, taking its target from $660 to $978, the single largest move in the recent run of changes. JP Morgan raised to $950 from $900 earlier this month, also keeping Overweight. The consensus mean target is $865.48, against a close of $807.48, implying 7.2% to the average and roughly 21% to the more aggressive Buy targets. Morgan Stanley stays at Equal-Weight with a $779 target, and RBC Capital holds at Sector Perform with an $810 target, so not every firm is in the bull camp. Factor scores tilt constructive: 12-month forward EPS year-on-year growth ranks at the 97th percentile, the analyst recommendation differential at the 97th percentile, and EPS momentum at the 83rd percentile over 30 days.

The Medicaid reimbursement data from the Centers for Medicare and Medicaid Services adds one note of caution to the otherwise positive setup. Medicaid dollars reimbursed for Regeneron drugs have fallen for three consecutive quarters, with the most recent quarterly reading down 26% against the same quarter a year earlier, reaching $83.5 million. None of the alt-data datasets here have been measured as leading indicators for the company's reported figures, so this cannot be read as a forecast of the print, but the streak of declines is a concrete data point on one part of the payer mix.

The two previous quarterly earnings prints both produced meaningful moves. The Q2 result in late July sent the stock up 9.7% on the day and 11% over the five trading days that followed. With the stock up 7.2% over the past week, already pricing in some degree of optimism, the October 30 print is where those targets and that positioning get their first real test.